AGER and Alzheimer disease: Because of the suggested involvement of RAGE in the pathological processes of dementia, and especially because of its suggested role in amyloid-β influx into the brain, inhibition of the amyloid-β–RAGE interaction was suggested to reduce the pathological processes of AD.46 Following this reasoning, a phase 3 clinical trial was conducted with patients with probable mild AD with an antagonist of RAGE but was ended earlier because futility criteria were met.47 However, whether inhibition of RAGE has a role in the prevention of dementia cannot be concluded from these data.